

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of December 2019

Commission File Number: 001-38746

---

**Taiwan Liposome Company, Ltd.**

(Translation of registrant's name into English)

---

Taiwan Liposome Company, Ltd.  
11F-1, No. 3 Yuanqu Street  
Nangang District,  
Taipei City, Taiwan 11503  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

---

**Departure of Directors**

On December 6, 2019, Burrill Life Sciences Capital Fund III, L.P. (the “Director”) resigned as a director of Taiwan Liposome Company, Ltd. (the “Company”) effective immediately due to the Director’s business considerations. The decision was not the result of any disagreement with the Company. The Company is grateful for the Director’s service to the Company.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**TAIWAN LIPOSOME COMPANY, LTD.**

Date: December 6, 2019

By: /s/ George Yeh

Name: George Yeh

Title: President